When false policy narratives make it difficult to obtain or enforce patents on the fruits of new branches of innovation, the cycle is interrupted, and progress stagnates.
Senators faced arguments against patents for biopharmaceutical innovation, based on flawed views that multiple patents for a single product are anti-competitive.
Patents cover inventions, not just products; for example, a mobile phone has thousands of patented inventions enabling its functions. Similarly, biopharmaceutical products rely on multiple discoveries to address complex biological challenges.
Biopharmaceutical innovation ecosystem works like a forest, where various patented discoveries act like branches supporting the growth of therapies and cures, requiring continuous investment and protection through patents.
Collection
[
|
...
]